and abbreviations: TRIPLE therapy: GC [pulse intravenous glucocorticoids (250-1000 mg methylprednisolone daily x 1-3 days) followed by oral glucocorticoid (≤0.5 mg/kg/day, maximum dose 40 mg/day) with taper] plus 2 additional immunosuppressive therapies, usually: a) MPAA plus belimumab, -orb) MPAA plus CNI -or-c) ELNT low-dose CYC plus belimumab (MPAA substituted for CYC after CYC course complete) DUAL therapy: GC [pulse intravenous glucocorticoids (250-1000 mg methylprednisolone daily x 1-3 days) followed by oral glucocorticoid (≤0.5 mg/kg/day, maximum dose 40 mg/day) with taper] plus one additional immunosuppressive therapy, usually MPAA or ELNT low-dose CYC Anti-CD20 therapy: rituximab or obinutuzumab AZA: Azathioprine BEL: Belimumab CNI: Calcineurin inhibitor therapies (cyclosporine, tacrolimus, voclosporin) CYC: Cyclophosphamide ELNT: EuroLupus Nephritis Trial ESKD: End stage kidney disease GC: Glucocorticoids HCQ: Hydroxychloroquine MPAA: Mycophenolic acid analogs (including